ONCOLOGY PRACTITIONERS THE 2 ND CONTINUOUS EDUCATION FOR HILTON HABTOOR HOTEL, LEBANON THE 2 ND CONTINUOUS EDUCATION FOR ONCOLOGY PRACTITIONERS

Size: px

Start display at page:

Download "ONCOLOGY PRACTITIONERS THE 2 ND CONTINUOUS EDUCATION FOR HILTON HABTOOR HOTEL, LEBANON THE 2 ND CONTINUOUS EDUCATION FOR ONCOLOGY PRACTITIONERS"

Duane Mathews
5 years ago
Views:

1 IN COLLABORATION WITH: 3 CE CREDITS THE LEBANESE ORDER OF PHARMACISTS THE 2 ND CONTINUOUS EDUCATION FOR ONCOLOGY PRACTITIONERS OCTOBER 27-28, 2017 HILTON HABTOOR HOTEL, LEBANON

3 Friday October 27, :00 Registration 1 C.E. Credit THE LEBANESE ORDER OF PHARMACISTS 14:00-14:15 Welcoming Note and Introduction Fadi Nasr 14:15-14:35 Cancer Patient Support Hani Nassar 14:15-14:20 BNA Main Achievements: Facts & Figures 14:20-14:30 Patients Testimonials 14:30-14:35 Future Projects 14:35-15:35 CLL Moderators: Souad Maalouf - Daisy Samaha - Tony Yammine - Perla Mousallem 14:35-14:55 Chemotherapy Free Era in CLL Colette Hanna Lecture Sponsored by Abbvie 14:55-15:05 Nurse Perspective Sahar Attieh 15:05-15:15 Clinical Pharmacy Perspective Nadine Zaineb 15:15-15:25 Cytogenetic Perspective Alain Chebly 15:25-15:35 Internal Medicine Souhail Araa 15:35-16:00 Coffee Break 16:00-16:30 Moderators: Rabih Tamim - Manale Dib Exploring New Directions in NSCLC Symposium Sponsored by Roche Fadi El Karak 16:30-17:30 Multiple Myeloma Moderators: Elie Rassy - Warde Semaan - Hala Sacre - Jean Claude Khairallah Hadi Ghanem - Arlette Hajjar 16:30-16:40 Case Presentation Ahmad Khalil 16:40-16:50 Nurse Perspective Paula Zoghby 16:50-17:00 Clinical Pharmacy Perspective Aline Hajj 17:00-17:10 Cytogenetic Perspective Rima Korban 17:10-17:20 Rheumatology Perspective Jeanine Mnassa 17:20-17:30 Oncology Perspective Fadi Nasr

4 Saturday October 28, :00 Registration 2 C.E. Credits THE LEBANESE ORDER OF PHARMACISTS 09:00-10:00 Breast Cancer Moderators: Marcel Massoud - Leony Antoun - Pierre Najem - Lamis Araa 09:00-09:12 Case Presentation Anthony Tarabay 09:12-09:24 Nurse Perspective Stephanie Kaddoum 09:24-09:36 Clinical Pharmacy Perspective Aline Saad 09:36-09:48 Surgeon Perspective Michel Hokayem 09:48-10:00 Oncology Perspective Marcel Massoud Moderators: Rita Rizk - Joya Dagher 10:00-10:30 Kisqali (Ribociclib): Power That Redefines First Line Symposium Sponsored by Novartis Discussion: Latife Karam Kirejian Fadi Nasr 10:30-11:00 Coffee Break Moderators: Zeina Hachem - Janah Madah 11:00-11:40 The Road Ahead in the Management of HR+ mbc Patients: Are There Differences Between CDK4/6 Inhibitors? Symposium Sponsored by Pfizer Georges Chahine Fadi Nasr 11:40-12:00 Psychology of Cancer Moderator: Rita Sakr 11:40-12:00 Evidence & Methods for Supporting Cancer Patients Toni Sawma 12:00-12:15 Advanced Nursing Practice Moderator: Gisele Hajal 12:00-12:15 Advanced Nursing Practice in Oncology Rima Sassine Kazan Moderators: Georges Maalouly - Lynn Abdo 12:15-13:15 Immunotherapy: Redefining Cancer Treatment: Pembrolizumab in NSCLC, UC, chl Symposium Sponsored by MSD Discussion: Randa Choueiri Fadi Nasr

5 Saturday October 28, 2017 Moderator: Nadine Bou Micheal - Noha Al Hachem 13:15-13:35 Optimizing Treatment Outcomes in Metastatic Gastric Cancer Symposium Sponsored by Eli Lilly Marwan Ghosn 2 C.E. Credits THE LEBANESE ORDER OF PHARMACISTS 13:35-14:35 Lunch Break 14:35-15:35 Lung Cancer Moderators: Georges Chahine - May Fakhoury - Rachel Ferekh 14:35-14:45 Case Presentation Roland Eid 14:45-14:55 Nurse Perspective Noura Merhi 14:55-15:05 Clinical Pharmacy Perspective Hanine Elias 15:05-15:15 Pulmonary Perspective Ihab Ibrahim 15:15-15:35 New Treatment in Lung Cancer Georges Chahine Moderator: Carole Deeb 15:35-16:05 Biosimilars: Pharmaceutical and Clinical Considerations Symposium Sponsored by Roche Fadi Farhat 16:05-16:30 Coffee Break 16:30-17:10 Current and Evolving Treatment Landscape for I-O in Head and Neck Cancers Symposium Sponsored by BMS Fadi Nasr Round Table: Georges Farha - Caroline Jabbour - Tanios Eid - Fares Azouri Clement Khoury - Sami Melki - Rami Saade - Antoine Melkane - Charbel Rameh 17:10-18:10 Colorectal Cancer Moderators: Fadi Nasr - Jinane Razzouk - Yasmine Yared - Joseph Amara 17:10-17:20 Case Presentation Evelyne Helou 17:20-17:30 Nurse Perspective Bernard Badr 17:30-17:40 Clinical Pharmacy Perspective Carole Deeb 17:40-17:50 Gastroenterology Perspective Antoine Abi Abboud 17:50-18:10 New Treatment in Colorectal Cancer Evelyne Helou

6 Notes

Non Small Cell Lung Cancer FIRST-LINE as a s ingle agent for the treatment of p atients with metastatic NSCLC whose tumors have high P D- L1 expression TPS 50%.

SECOND-LINE as a s ingle agent for the treatment of patients with metastatic N SCLC whose tumors express PD- L1 (TPS 1%) w ith disease progression o n o r a fter platinum-containing chemotherapy.

7 Non Small Cell Lung Cancer FIRST-LINE as a s ingle agent for the treatment of p atients with metastatic NSCLC whose tumors have high P D- L1 expression TPS 50%. FIRST-LINE in combination with pemetrexed and carboplatin, for the treatment of patients with metastatic nonsquamous NSCLC. SECOND-LINE as a s ingle agent for the treatment of patients with metastatic N SCLC whose tumors express PD- L1 (TPS 1%) w ith disease progression o n o r a fter platinum-containing chemotherapy. Urothelial Carcinoma FIRST-LINE for the treatment of patients with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatin-containing chemotherapy. SECOND-LINE for the treatment of patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy Classical Hodgkin Lymphoma For the treatment of adult and pediatric patients with refractory chl, or who have relapsed after 3 or more prior lines of therapy Melanoma FIRST & SECOND-LINE for the treatment of patients with unresectable or metastatic melanoma Head and Neck Squamous Cell Cancer For the treatment of patients with recurrent or metastatic HNSCC with disease progression on or after platinumcontaining chemotherapy. Reference: Keytruda Lebanon Summary of Product Characteristics July 2017 TPS: Tumor Proportion Score PD-L: Programmed death Ligand MSD ONCOLOGY Lebanon : Azar Bldg. 2nd Floor Beirut, Tel: Fax: Full prescribing information is available upon request. For further inquiries please at:dpoc_le vant@merck.com OCT-2018-LEB-ONCO

CEOP 2017 would like to thank the below sponsors for their contribution to the success of its annual congress Organised by: 4 th FLOOR, QUBIC CENTER, DAOUD

8 CEOP 2017 would like to thank the below sponsors for their contribution to the success of its annual congress Organised by: 4 th FLOOR, QUBIC CENTER, DAOUD AMMOUN STREET, HORSH TABET - SIN EL FIL P.O BOX: BEIRUT, LEBANON TEL: /1/2/3 FAX Ext INFOMED@INFOMEDWEB.COM WEB:

The Annual Conference of the Lebanese Society of Family Medicine

The Annual Conference of the Lebanese Society of Family Medicine 2017 CARE OF THE ELDERLY: Simplifying Complexity September 29 th - October 1 st CME Credits provided by LOP & AAFP September 29 th - October